Evaluation of the efficacy and tolerability of 4 mg dienogest in women with adenomyosis and BMI >30
This study found that 4mg of dienogest was effective and well-tolerated in 81% of obese women with adenomyosis, improving symptoms, though adherence to lifestyle changes was crucial.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This prospective study evaluated the efficacy and tolerability of 4 mg dienogest in 110 women aged 30–40 with ultrasonography-confirmed adenomyosis, severe dysmenorrhea, and BMI >30, treated over 20 weeks with 8 weeks of 4 mg dienogest followed by tapering to 2 mg once daily, alongside dietary counseling to reduce carbohydrate intake and implement lifestyle modifications. Symptom improvement for menorrhagia, dysmenorrhea, dyspareunia, and chronic pelvic pain was reported in 81% of participants, while adverse effects included headache (15%), breast discomfort (10%), and mild weight gain (8%); irregular bleeding led to discontinuation in 3%. The paper notes a limitation that women who needed ongoing 4 mg dosing beyond eight weeks showed poor adherence to dietary modifications, and outcomes may therefore be influenced by adherence. This paper is centrally about adenomyosis — it tests a higher-dose dienogest regimen in obese women with adenomyosis-related symptoms.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
7,253 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Background
Methods
Results
Conclusion
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (21)
- A systematic review and Bayesian analysis of the adverse effects of dienogest via openalex
- Comparison of the efficacy of dienogest and GnRH-a after endometriosis surgery via openalex
- Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis via openalex
- Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis via openalex
- Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability via openalex
- Systematic review and Meta-analysis of efficacy and safety of dienogest in treatment of endometriosis via openalex
- The Efficacy of Dienogest in Reducing Disease and Pain Recurrence After Endometriosis Surgery: a Systematic Review and Meta-Analysis via openalex
- Use of dienogest in endometriosis: a narrative literature review and expert commentary via openalex
- W4295138702 via openalex
- W4385232812 via openalex
- W4391310044 via openalex
- W4392597190 via openalex
- W4393396201 via openalex
- W4211081176 via openalex
- W2024314011 via openalex
- W2046136036 via openalex
- W2163315477 via openalex
- W2608334651 via openalex
- W3005953879 via openalex
- W3203498372 via openalex
- W2021687464 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00